Moderna vaccine succeeds in early-stage skin cancer study with Merck’s Keytruda
Bio Pharma Dive
DECEMBER 13, 2022
The positive data are the most significant findings for the mRNA developer’s pipeline of experimental treatments outside of infectious diseases, where it has reaped billions from COVID-19 vaccine sales.
Let's personalize your content